Legorreta Pablo G.
Insider CIK 1507678 · EPZM Director, 10% owner · RPRX CEO, Chairman of the Board, Director, 10% owner · PROK Director, 10% owner
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| RPRX Royalty Pharma plc | G Gift deriv | 2026-08-07 | 2026-08-07 | 30,000 | — | $0 | 662,701 | SEC↗ |
| RPRX Royalty Pharma plc | G Gift deriv | 2026-08-07 | 2026-08-07 | 30,000 | — | $0 | 662,701 | SEC↗ |
| RPRX Royalty Pharma plc | A Award | 2026-08-05 | 2026-08-07 | 65,216 | — | $0 | 1,307,820 | SEC↗ |
| RPRX Royalty Pharma plc | A Award | 2026-08-05 | 2026-08-07 | 65,216 | — | $0 | 1,307,820 | SEC↗ |
| PROK PROKIDNEY CORP. | A Award deriv | 2026-05-28 | 2026-05-29 | 135,000 | — | $0 | 135,000 | SEC↗ |
| RPRX Royalty Pharma plc | A Award | 2026-05-06 | 2026-05-08 | 143,821 | — | $0 | 1,242,604 | SEC↗ |
| RPRX Royalty Pharma plc | A Award | 2026-02-11 | 2026-02-13 | 157,828 | — | $0 | 1,098,783 | SEC↗ |
| RPRX Royalty Pharma plc | A Award | 2025-11-05 | 2025-11-07 | 36,559 | — | $0 | 940,955 | SEC↗ |
| RPRX Royalty Pharma plc | G Gift deriv | 2025-08-08 | 2025-08-08 | 60,000 | — | $0 | 692,701 | SEC↗ |
| RPRX Royalty Pharma plc | A Award | 2025-08-06 | 2025-08-08 | 21,901 | — | $0 | 904,396 | SEC↗ |
| PROK PROKIDNEY CORP. | C Conversion deriv | 2025-06-03 | 2025-06-05 | 3,823,996 | — | $0 | 84,283,430 | SEC↗ |
| PROK PROKIDNEY CORP. | C Conversion deriv | 2025-06-03 | 2025-06-05 | 3,823,996 | — | $0 | 84,283,430 | SEC↗ |
| PROK PROKIDNEY CORP. | C Conversion | 2025-06-03 | 2025-06-05 | 3,823,996 | — | $0 | 26,441,905 | SEC↗ |
| PROK PROKIDNEY CORP. | J Other | 2025-06-03 | 2025-06-05 | 3,823,996 | — | $0 | 22,617,909 | SEC↗ |
| PROK PROKIDNEY CORP. | A Award deriv | 2025-05-29 | 2025-06-02 | 125,862 | — | $0 | 125,862 | SEC↗ |
| RPRX Royalty Pharma plc | A Award deriv | 2025-05-16 | 2025-05-20 | 13,356,742 | — | $0 | 13,356,742 | SEC↗ |
| RPRX Royalty Pharma plc | J Other deriv | 2025-05-16 | 2025-05-20 | 857,138 | — | $0 | 857,138 | SEC↗ |
| RPRX Royalty Pharma plc | J Other | 2025-05-16 | 2025-05-20 | 530,348 | — | $0 | 882,495 | SEC↗ |
| RPRX Royalty Pharma plc | G Gift deriv | 2025-05-12 | 2025-05-14 | 867,180 | — | $0 | 0 | SEC↗ |
| RPRX Royalty Pharma plc | G Gift deriv | 2025-05-12 | 2025-05-14 | 867,180 | — | $0 | 0 | SEC↗ |
| RPRX Royalty Pharma plc | A Award | 2025-05-08 | 2025-05-09 | 288,352 | — | $0 | 352,147 | SEC↗ |
| PROK PROKIDNEY CORP. | C Conversion deriv | 2025-02-04 | 2025-02-06 | 532,535 | — | $0 | 88,107,426 | SEC↗ |
| PROK PROKIDNEY CORP. | C Conversion deriv | 2025-02-04 | 2025-02-06 | 532,535 | — | $0 | 88,107,426 | SEC↗ |
| PROK PROKIDNEY CORP. | J Other | 2025-02-04 | 2025-02-06 | 532,535 | — | $0 | 22,617,909 | SEC↗ |
| PROK PROKIDNEY CORP. | C Conversion | 2025-02-04 | 2025-02-06 | 532,535 | — | $0 | 23,150,444 | SEC↗ |
| PROK PROKIDNEY CORP. | P Buy | 2024-06-13 | 2024-06-14 | 22,617,909 | $2.42 | $54.74M | 22,617,909 | SEC↗ |
| PROK PROKIDNEY CORP. | A Award deriv | 2024-05-30 | 2024-06-03 | 62,558 | — | $0 | 62,558 | SEC↗ |
| PROK PROKIDNEY CORP. | C Conversion deriv | 2024-02-05 | 2024-02-06 | 748,952 | — | $0 | 88,639,961 | SEC↗ |
| PROK PROKIDNEY CORP. | C Conversion deriv | 2024-02-05 | 2024-02-06 | 748,952 | — | $0 | 88,639,961 | SEC↗ |
| PROK PROKIDNEY CORP. | C Conversion | 2024-02-05 | 2024-02-06 | 748,952 | — | $0 | 748,952 | SEC↗ |
| PROK PROKIDNEY CORP. | J Other | 2024-02-05 | 2024-02-06 | 748,952 | — | $0 | 0 | SEC↗ |
| RPRX Royalty Pharma plc | J Other | 2023-11-16 | 2023-11-16 | 383,000 | — | $0 | 63,795 | SEC↗ |
| PROK PROKIDNEY CORP. | C Conversion deriv | 2023-10-30 | 2023-11-01 | 5,289,055 | — | $0 | 89,388,913 | SEC↗ |
| PROK PROKIDNEY CORP. | C Conversion deriv | 2023-10-30 | 2023-11-01 | 5,289,055 | — | $0 | 89,388,913 | SEC↗ |
| PROK PROKIDNEY CORP. | J Other | 2023-10-30 | 2023-11-01 | 5,289,055 | — | $0 | 0 | SEC↗ |
| PROK PROKIDNEY CORP. | C Conversion | 2023-10-30 | 2023-11-01 | 5,289,055 | — | $0 | 5,289,055 | SEC↗ |
| PROK PROKIDNEY CORP. | A Award deriv | 2023-06-29 | 2023-07-03 | 48,128 | — | $0 | 48,128 | SEC↗ |
| RPRX Royalty Pharma plc | P Buy | 2023-06-28 | 2023-06-28 | 130,000 | $29.51 | $3.84M | 600,000 | SEC↗ |
| RPRX Royalty Pharma plc | P Buy | 2023-06-13 | 2023-06-13 | 45,000 | $32.78 | $1.48M | 470,000 | SEC↗ |
| RPRX Royalty Pharma plc | P Buy | 2023-06-12 | 2023-06-13 | 45,000 | $33.00 | $1.49M | 425,000 | SEC↗ |
| RPRX Royalty Pharma plc | P Buy | 2023-05-24 | 2023-05-24 | 150,000 | $32.25 | $4.84M | 380,000 | SEC↗ |
| RPRX Royalty Pharma plc | P Buy | 2023-05-17 | 2023-05-17 | 69,612 | $32.94 | $2.29M | 230,000 | SEC↗ |
| RPRX Royalty Pharma plc | P Buy | 2023-05-16 | 2023-05-17 | 160,388 | $33.57 | $5.38M | 160,388 | SEC↗ |
| RPRX Royalty Pharma plc | G Gift deriv | 2023-05-12 | 2023-05-15 | 10,269 | — | $0 | 692,701 | SEC↗ |
| RPRX Royalty Pharma plc | G Gift deriv | 2023-05-12 | 2023-05-15 | 10,269 | — | $0 | 0 | SEC↗ |
| RPRX Royalty Pharma plc | G Gift | 2022-12-30 | 2023-11-16 | 292,190 | — | $0 | 292,190 | SEC↗ |
| EPZM Epizyme, Inc. | D To issuer deriv | 2022-08-12 | 2022-08-16 | 8,994 | — | $0 | 0 | SEC↗ |
| EPZM Epizyme, Inc. | D To issuer deriv | 2022-08-12 | 2022-08-16 | 8,060 | — | $0 | 0 | SEC↗ |
| EPZM Epizyme, Inc. | U Tender | 2022-08-12 | 2022-08-16 | 31,933,334 | — | $0 | 0 | SEC↗ |
| PROK PROKIDNEY CORP. | A Award deriv | 2022-07-11 | 2022-07-13 | 10,500,000 | — | $0 | 10,500,000 | SEC↗ |
| PROK PROKIDNEY CORP. | A Award deriv | 2022-07-11 | 2022-07-13 | 94,677,968 | — | $0 | 94,677,968 | SEC↗ |
| PROK PROKIDNEY CORP. | A Award deriv | 2022-07-11 | 2022-07-13 | 94,677,968 | — | $0 | 94,677,968 | SEC↗ |
| EPZM Epizyme, Inc. | A Award deriv | 2022-05-17 | 2022-05-19 | 41,006 | $0.56 | $23.0K | 41,006 | SEC↗ |
| EPZM Epizyme, Inc. | A Award deriv | 2022-05-17 | 2022-05-19 | 8,994 | — | $0 | 8,994 | SEC↗ |
| RPRX Royalty Pharma plc | J Other | 2022-04-14 | 2022-04-15 | 462,031 | — | $0 | 0 | SEC↗ |
| RPRX Royalty Pharma plc | J Other | 2022-04-14 | 2022-04-15 | 350,000 | — | $0 | 63,795 | SEC↗ |
| EPZM Epizyme, Inc. | P Buy | 2022-01-31 | 2022-02-01 | 22,666,667 | $1.50 | $34.00M | 31,833,334 | SEC↗ |
| RPRX Royalty Pharma plc | J Other deriv | 2021-06-30 | 2022-04-15 | 73,332 | — | $0 | 73,332 | SEC↗ |
| EPZM Epizyme, Inc. | A Award deriv | 2021-06-11 | 2021-06-15 | 40,559 | $8.53 | $346.0K | 40,559 | SEC↗ |
| EPZM Epizyme, Inc. | A Award deriv | 2021-06-11 | 2021-06-15 | 8,060 | — | $0 | 8,060 | SEC↗ |
| RPRX Royalty Pharma plc | C Conversion deriv | 2021-05-07 | 2021-05-11 | 104,041 | — | $0 | 0 | SEC↗ |
| RPRX Royalty Pharma plc | C Conversion deriv | 2021-05-07 | 2021-05-11 | 128,459 | — | $0 | 0 | SEC↗ |
| RPRX Royalty Pharma plc | C Conversion | 2021-05-07 | 2021-05-11 | 1,284,590 | — | $0 | 1,284,590 | SEC↗ |
| RPRX Royalty Pharma plc | C Conversion | 2021-05-07 | 2021-05-11 | 1,040,410 | — | $0 | 1,040,410 | SEC↗ |
| RPRX Royalty Pharma plc | J Other deriv | 2021-03-23 | 2022-04-15 | 16,012 | — | $0 | 2,862,363 | SEC↗ |
| RPRX Royalty Pharma plc | J Other deriv | 2021-03-23 | 2022-04-15 | 15,947 | — | $0 | 2,850,640 | SEC↗ |
| RPRX Royalty Pharma plc | C Conversion deriv | 2020-10-20 | 2022-04-15 | 42,842 | — | $0 | 5,748,271 | SEC↗ |
| RPRX Royalty Pharma plc | C Conversion deriv | 2020-10-20 | 2022-04-15 | 42,842 | — | $0 | 5,791,113 | SEC↗ |
| RPRX Royalty Pharma plc | C Conversion deriv | 2020-10-20 | 2022-04-15 | 42,842 | — | $0 | 1,626,857 | SEC↗ |
| RPRX Royalty Pharma plc | C Conversion | 2020-10-20 | 2022-04-15 | 428,420 | — | $0 | 922,170 | SEC↗ |
| RPRX Royalty Pharma plc | C Conversion deriv | 2020-06-18 | 2020-06-22 | 12,331 | — | $0 | 962 | SEC↗ |
| RPRX Royalty Pharma plc | C Conversion deriv | 2020-06-18 | 2020-06-22 | 11,850 | — | $0 | 924 | SEC↗ |
| RPRX Royalty Pharma plc | P Buy | 2020-06-18 | 2020-06-22 | 10,000 | $28.00 | $280.0K | 10,000 | SEC↗ |
| RPRX Royalty Pharma plc | P Buy | 2020-06-18 | 2020-06-22 | 10,000 | $28.00 | $280.0K | 10,000 | SEC↗ |
| RPRX Royalty Pharma plc | C Conversion | 2020-06-18 | 2020-06-22 | 123,310 | — | $0 | 123,310 | SEC↗ |
| RPRX Royalty Pharma plc | C Conversion | 2020-06-18 | 2020-06-22 | 118,500 | — | $0 | 118,500 | SEC↗ |
| RPRX Royalty Pharma plc | C Conversion deriv | 2020-06-16 | 2022-04-15 | 49,375 | — | $0 | 1,669,699 | SEC↗ |
| RPRX Royalty Pharma plc | C Conversion deriv | 2020-06-16 | 2022-04-15 | 49,375 | — | $0 | 5,797,646 | SEC↗ |
| RPRX Royalty Pharma plc | C Conversion deriv | 2020-06-16 | 2022-04-15 | 49,375 | — | $0 | 5,748,271 | SEC↗ |
| RPRX Royalty Pharma plc | C Conversion | 2020-06-16 | 2022-04-15 | 493,750 | — | $0 | 493,750 | SEC↗ |
| RPRX Royalty Pharma plc | A Award deriv | 2020-06-15 | 2022-04-15 | 1,719,074 | — | $0 | 1,719,074 | SEC↗ |
| RPRX Royalty Pharma plc | A Award deriv | 2020-06-15 | 2020-06-22 | 12,774 | — | $0 | 12,774 | SEC↗ |
| RPRX Royalty Pharma plc | A Award deriv | 2020-06-15 | 2020-06-22 | 138,479 | — | $0 | 138,479 | SEC↗ |
| RPRX Royalty Pharma plc | A Award deriv | 2020-06-15 | 2020-06-22 | 13,293 | — | $0 | 13,293 | SEC↗ |
| RPRX Royalty Pharma plc | A Award deriv | 2020-06-15 | 2020-06-22 | 4,868,033 | — | $0 | 4,868,033 | SEC↗ |
| RPRX Royalty Pharma plc | A Award deriv | 2020-06-15 | 2020-06-22 | 942,738 | — | $0 | 942,738 | SEC↗ |
| RPRX Royalty Pharma plc | A Award deriv | 2020-06-15 | 2020-06-22 | 112,156 | — | $0 | 112,156 | SEC↗ |
| RPRX Royalty Pharma plc | A Award deriv | 2020-06-15 | 2020-06-22 | 1,677,574 | — | $0 | 1,677,574 | SEC↗ |
| EPZM Epizyme, Inc. | A Award deriv | 2020-05-29 | 2020-06-02 | 14,103 | — | $0 | 14,103 | SEC↗ |
| EPZM Epizyme, Inc. | A Award | 2020-02-11 | 2020-02-13 | 2,500,000 | $20.00 | $50.00M | 9,166,667 | SEC↗ |
| EPZM Epizyme, Inc. | A Award deriv | 2019-11-06 | 2019-11-08 | 34,408 | — | $0 | 34,408 | SEC↗ |